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ABSTRACT
There remains a paucity of predictive models to evaluate the suitability of excipients or excipient mixtures for
dry powder inhalers because a large number of interdependent variables affect both formulation and inhaler
performance. The problem is compounded by empirical studies that are performed under different
experimental conditions which make data comparison difficult. An easily calculable molecular parameter, the
Parachor, relates structural constants to surface tension. When applied in conjunction with results obtained
from inverse gas chromatography, the Parachor can be used to calculate adhesive and cohesive surface
energies between excipients and active pharmaceutical ingredients. Values calculated from the Parachor are
consistent with qualitative hypotheses and agree reasonably well with published quantitative results. The
ability to both achieve and predict the free particle fraction from Parachor derived surface energy data
represents a new paradigm worthy of further perusal.
KEY WORDS: Dry powder inhaler, lactose, excipient, aerosolization, fine particle fraction, adhesive energy, cohesive
energy, lung deposition, inverse gas chromatography, cohesive adhesive balance, particle-particle interactions,
Parachor
INTRODUCTION
A recent editorial painted a bleak picture
regarding the understanding of the relationship
between the physicochemical characteristics of
the most widely used carrier in adhesive
mixtures for dry powder inhalers, lactose, and
the performance of those dry powder inhalers.
The author cited a list of factors responsible for
this situation and recommended areas where
further research might prove fruitful in turning
information into knowledge (1). To this effect,
others (2) have suggested that standard
experimental conditions and data reporting
criteria be adopted so that a database of results
may be constructed to facilitate performance
prediction. The urgency of the need for a
predictive model is further exemplified when
two APIs are used in combination and the ratio
of the APIs during co-deposition into the lungs
affects efficacy. Particle engineering techniques
such as sonocrystallization have emerged, partly
in response to a lack of predictive API/
excipient interaction, mixing and aerosolization
models (3).*Corresponding author: Alcon Research Inc., 6405 South Freeway, 
Mail Stop R123, Fort  Worth, Texas, 76063, USA, Tel: 8176896086,  
E-mail: shireesh.apte@alconlabs.com
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This review attempts to collate disparate
information from the literature into a coherent
whole. While recognizing that data generated
under different experimental conditions/
methods with different materials may not yield
mathematically exquisite correlations, general
relationships may still be discernible.
Physicochemical data will be examined to
ascertain whether qualitative or quantitative
predictions relating to the degree of
cohesiveness and/or adhesiveness, fine particle
fraction (FPF) or aerosol performance can be
made a priori. To this effect, a new term is
introduced, the Cohesive Index (CI), that is
consistent with bulk surface energy predictions
and can be correlated with a fundamental
property of molecular structure, the Parachor.
Data obtained from single crystal
measurements using atomic force microscopy
(cohesive-adhesive balance (CAB) of adhesive
mixtures) will be compared to those obtained
using ‘bulk’ methods such as inverse gas
chromatography (dispersive (γLW) surface free
energy and the electron acceptor (γ+) and
electron donor (γ-) components of the polar
surface free energy of the individual
constituents).  In addition, the validity of the
‘passivation hypothesis’ to explain the benefit
of mixing lactose coarse and fine particles on
the FPF will be examined based on quantitative
surface energy values generated by inverse gas
chromatography.
The totality of the information presented in this
paper may hence serve as a useful guide in
choosing a particular excipient (or a processed
excipient whose surface energy has been
altered) or a particular mixture of excipients for
a particular API to yield a theoretical maximum
fine particle (respirable) fraction (FPF). The
fact that this paper succeeds in arriving at
(admittedly crude) quantitative predictive
relationships between readily calculable
structural constants and adhesive energy
indicates that a more rigorous and exhaustive
data mining of the existing literature can lead
toward a better understanding of surface and
interface chemistry of dry powders. Specific
structural parameters such as the Parachor can
serve as useful surrogates to estimate surface
interactions and analysis (and experiments)
along these lines of inquiry seem to be
endeavors worthy of pursuit.
Dry powder inhalation formulations are usually
composed of micronized drug particles and an
excipient carrier. The carrier is instrumental in
assuring dosing uniformity during aero-
solization and flowability during manufacturing.
The design of the formulation must meet
contradictory requirements. The adhesive force
between drug and carrier particles must be of
such a magnitude so as to overcome the drug-
drug and excipient-excipient cohesive forces.
This is essential to facilitate the uniform
dispersion of the drug in the drug-excipient
blend and while the powder is being
aerosolized. On the other hand the adhesive
force between the drug and carrier particles
must be weak enough (but not too weak (56))
so that the drug particles can be released from
the excipient particles upon aerosolization to
form an acceptable FPF. The size of the FPF
must be below 5 µm (with a predominantly
submicron distribution) to avoid alveolar
macrophage uptake (4) and enable penetration
deep into the lungs (5), although the
dependence of the latter requirement on
particle size seems to diminish as the density of
the particles decreases (6). 
A number of factors determine particle-particle
interactions in adhesive mixtures, e.g., surface
energy (7), surface morphology (roughness (8),
asperity), shape (9), particle size and size
distribution (10), order of mixing of ingredients
(11), polymorphic form (12), amorphicity (13),
humidity (14) and triboelectrification (15).
Many of these factors are interdependent, that
is, they cannot be varied independently of each
other. In addition, the FPF or the respirable
fraction is also affected by particle processing
history (16) and inhaler design (17).
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DISCUSSION
Evidence in the literature generally supports the
proposition that the addition of fines to carrier
material improves the drug aerosolization and
the FPF or respirable dose of cohesive APIs
(18). A similar effect is seen with carrier
particles that have different mean diameters and
similar polydispersity, the FPF increased as the
mean diameter decreased (19). Conversely, the
removal of fines from carriers decreases drug
aerosolization (20) as does an increase in carrier
size (21).
At greater drug to carrier ratios (1:36), the
delivery device and lactose carrier particle size
distribution were found to significantly
influence FPF (22). This effect was not
significant at lesser drug to carrier ratios
(1:400). The FPF was directly proportional to
the device air flow rate regardless of the drug to
carrier ratio, however the absolute value of FPF
increased as the drug to carrier ratio decreased
(from 1:1 to 1:8) (23). Another study,
performed at drug to carrier ratios between 1:5
and 1:85 found the greatest FPF at a ratio of
1:10, with a decrease at a ratio of 1:5 and
progressive decrease at ratios greater than 1:10
(24). The FPF therefore seems to depend in a
bell curve manner to the drug loading;
decreasing at both low and high loadings and
becoming greater at medium loadings.
Another study that investigated the deposition
of budesonide from lactose carriers (drug to
carrier ratio was 1:100) with different size
distributions (broad with lesser mean diameter,
narrow with greater mean diameter and a
mixture of the two), showed that the FPF was
greater for the lactose with the broad size
distribution and lesser mean diameter (25). It
also showed that the lung deposition of the
99mTC labeled lactose carriers was independent
of particle size distribution thus concluding that
pulmonary deposition was not a limiting factor
for lactose (of different particle size
distribution) selection. 
Recrystallization of lactose from varying ratios
of acetone/water mixtures produced particles
that exhibited an increased elongation ratio,
decreased mean diameter and a shift from the α
to the β polymorph as the acetone proportion
in the solvent increased. The FPF of salbutamol
sulfate, when mixed with these recrystallized
carriers (1: 67.5 ratio), increased >4 times
compared with that of the commercial grade
lactose (26). A similar effect was observed with
mannitol recrystallized form acetone. In this
case, both the fine particle fraction and the
elongation ratio of the recrystallized mannitol
were greater than the commercial grade and
produced an increase of FPF when mixed with
salbutamol in a 1:67.5 (drug: carrier) ratio (27).
The enhancement appears to have an upper
limit however, beyond which increasing the
elongation ratio does not affect FPF (28).
The guiding principle for formulating powders
for DPI seems to be to obtain/prepare a carrier
(mixture of lactose fines and lactose coarse
particles) and mix the micronized API with this
carrier. The hypothesis is that the ‘high energy
sites’ on the coarse particles (29) are occupied
or passivated by the fines such that the API
particles are forced to adhere to the ‘lower
energy sites’ on the coarse carrier particles (30).
The passivation of the high energy sites of the
coarse carrier particles can also be performed
by utilizing ‘force control agents’ (31) or FCAs.
FCAs may consist of hydrophobic surfactants,
polymers (32) or lipids. 
The net surface free energy and polydispersity
of a blend of fine and coarse particles is greater
than that of a carrier consisting only of coarse
particles (33). Such a situation has been
proposed to lead to an optimal size of the
carrier-API agglomerates that are subject to
greater de-agglomeration forces in an airstream
because these forces are proportional (to an
upper limit) to the square (drag force) or cube
(collisions) of the diameter of the agglomerate
(34). As a result, a greater percentage of API
incorporated with the fine/coarse excipient
blend may undergo de-agglomeration upon
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aerosolization, thereby leading to greater
deposition in the deep lung (35). 
Using the seminal ideas of Bertholet, who
proposed that the interfacial adhesive work
between two surfaces is the geometric mean of
the cohesive work of the individual surfaces,
and that of Fowkes (36), who proposed that
intermolecular forces are additive, the Gibbs
free energy of adhesion or the work of
adhesion between two substances can be
expressed in terms of the surface energy
components as shown in Equation 1 (37, 38).
Eq. 1
Where,
The subscripts d, e and l represent the drug,
excipient and the apolar liquid respectively, the
first four terms on the right hand side of the
equation represent the dispersive or Liftshitz-
van der Waals component of the surface free
energy and the last two terms represent the
specific acid-base component of the surface
free energy, further consisting of the electron
acceptor (acid) component, γ+, and the electron
donor (base) component, γ-. 
The apolar solvent used for most of the studies
cited in the literature is the propellent 2H, 3H
deca f l uo ropen t ane ,  t h e   γ γ γlLW l l, + −and
parameters for this liquid being 13.59, 0 and 0
respectively (39). Adhesive surface free energies
are expressed as absolute (positive) values (for
ease of interpretation) throughout this report.
In addition, where the word “lactose” is not
preceded by the word “non-micronized”, it
represents non-micronized lactose.
Using the technique of inverse gas
chromatography (IGC), the acid-base
contribution to the non-dispersive component
of free energy can be found from alternately
probing the adsorbate surface to be studied
with acidic and basic polar probe compounds
as shown in Equation 2.
Eq. 2[ ] [ ]{ }ΔG aNAB a l s l s= ++ − − +2 1 2 1 2γ γ γ γ/ /
Where,
a is the probe molecular cross sectional area,
Na, is Avagadro’s number, is the electronγ l
+
acceptor (acidic) component of the non-
dispersive surface free energy component for
the liquid (vapor) probe, is the electronγ l−
donor (basic) component of the non-dispersive
surface free energy component of the liquid
(vapor) probe,  is the electron donor (basic)γ s−
component of the non-dispersive surface free
energy of the solid adsorbate and   is theγ s+
electron acceptor (acidic) component of the
non-dispersive surface free energy of the solid
adsorbate.  is the acid-base component ofΔG AB
the non-dispersive free energy of the solid
expressed in KJ/mole.
When basic probe compounds such as
tetrahydrofuran, toluene or ethyl acetate are
used,  thereby enabling determination ofγ l+ = 0
. When acidic probe compounds such asγ s+
chloroform or dichloromethane are used,
, thereby enabling determination of .γ l− = 0 γ s−
The value of  for mannitol (Table 2) wasγ s+
calculated using 4.7 KJ/mole (40) , 2.9 X 10-19
and 20 mJ/m2 as values for , crossΔG AB
sectional molecular area and  (for the basicγ l−
probe, tetrahydrofuran) respectively. Similarly,
to calculate the  for micronized lactose, a γ s+
value of 5.2 KJ/mol (41) was used usingΔG AB
ethyl acetate as the polar probe at 25EC.
Although every attempt was made to compare
attributes obtained for similarly processed
materials under comparable conditions, in many
instances, values for all the three attributes,
namely, were not reported in theγ γ γaLW d, + −and d
same reference manuscript or were not in the
same units (42) (e.g. salmeterol). Therefore,
some of the values (described above) have been
extracted from different manuscripts from the
most reported attribute of the specific free
energy of adsorption of polar probes. For those
drugs where a significant difference between
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values calculated from different methods
existed in the literature, the values that were
most consistent with the structure of the drug
were applied. For example, for budesonide,
when the cross sectional molecular area and γ l−
values (43) for the polar basic probe, ethyl
acetate, of 3.293 X 10-19 m2 and 19.2 mJ/m2,
were used with the calculated value ofΔG AB
10.52 KJ/mole (44),   was calculated as 36.64γ d+
mJ/m2.  was estimated to be 45.8 from theγ d−




of the electron acceptor component of the free
energy (as well 
as the reported value of 68.47 mJ/m2 for )γ dLW
appears unduly high compared to similar
steroidal drugs.Therefore, of 49.07,γ γ γdLW d, + and d-
0.34 and 22.47 mJ/m2 were used as shown in
reference 39. Furthermore, particle size
distribution data or processing history was
often not reported, or was different, when
calculated descriptors of , wereγ γ γdLW d, + −and d
pooled together from different references. 
In Table 1, the attributes of pKa through 
melting point were obtained from the open
data drug and drug target databases at
www.drugbank.ca or at www.chemspider.com.
Values of  for micronizedγ γ γdLW d, + and d-
(salbutamol, budesonide and formoterol) were
taken from reference 39. Values for micronized
ipratropium were taken from reference 56.
Values for mometasone were taken from
reference 57 as were values of  ,  forγ γd d+ −and
salmeterol. The value of  for micronizedγ dLW
salmeterol was taken from reference 42.
If either γ+ or  γ- of the material is < 1, then the
material can be classified as being monopolar
(47) with either the Lewis acid, or the Lewis
base component of the polar surface free
energy dominating. 
If both γ+ or γ- of the material is >1, then the
material is bipolar, capable of accepting as well
as donating electrons. Monopolar surfaces can
interact strongly with other monopolar surfaces
of opposite sign (acid-base interactions) and
with dipolar surfaces. 
Table 1 Physico-chemical characteristics of APIs used in dry powder inhalers
ATTRIBUTE SALBUTAMOL BUDESONIDE MOMETASONE FLUTICASONE FORMOTEROL SALMETEROL IPRATROPIUM
pKa 14.18 14.91 13.85 14.48 14.21 14.18 NA
H-acceptor 4 6 4 4 5 5.00 2.00
H-donor 4 2 2 1 4 4.00 1.00
Polar surface area (A2) 72.72 93.06 74.6 80.67 90.82 81.95 46.53
Refractivity 67.87 116.11 110.29 121.65 97.87 122.39 105.90
Polarizability (αp)
(X1024 )(C/m2.V)
28.66 47.11 43.82 48.94 35.56 50.60 37.43




207.6 336.4 379.2 323.16 279.1 379.7 373.7
Water solubility (g/L) 3 0.0457 0.00523 0.0114 0.0416 0.0023 0.0007


























625.2 986.7 1034.1 931.1 829.2 930.3 810.3
Dispersive surface energy,
  (mJ/m2)γ d
LW 46.49 49.07 47 47.93* 48.51 45.25 44.90
Electron acceptor
component of surface
energy,   (mJ/m2)γ d
+
8.25 0.34 0.1 Not known 0.11 0.13 26.00
Electron donor component
of surface energy,   γ d
−
(mJ/m2)
18.48 22.47 32 Not known 35.04 41.80 8.7
*Calculated from Parachor,, Not known: Not available from the literature, NA Available
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pKa 12.17 12.39 13.38 14.29 12.17 NA
H-acceptor 11 11 6 4 11 11.00
H-donor 8 8 6 4 8 8.00
Polar surface area (A2) 189.53 189.53 121.38 80.92 189.53 NA
Refractivity 68.34 68.77 38.4 26.48 68.34 NA
Polarizability (C/m2.V) 31.32 31.32 16.82 11.62 31.32 NA
Rotatable bonds 4 5 5 3 4 NA
Water solubility (g/L) 586 824 216 1160 586 689.00





LW 40.74 43.2 47.9 Not known 42.3 42.90
Electron acceptor component of surface
Energy,  (mJ/m2)γ e
+ 0.15 1.04 9.05 Not known 8.95 5.90
Electron donor component of surface
energy,  (mJ/m2)γ e−
35.51 51.3 19.9 Not known 29.3 26.10
NA Not Available
According to this definition, salbutamol and
ipratropium can be classified as bipolar APIs
(the rest being monopolar) while all the
excipients are bipolar except for non-
micronized lactose monohydrate. For bipolar
APIs, the adhesive interactions with the
excipients are expected to be greater than for
monopolar APIs which is indeed the case
(Table 3). This is because the work of adhesion
for the former pair also incorporates
contributions from the polar component in
addition to those from the dispersive
component (Keesom, Debye and London
interactions).
The values for the drug-excipient  adhesive 
energy (DE)  for  salbutamol,  mometasone,
salmeterol and formoterol with the excipients
lactose, sucrose and micronized lactose agree to
± 5% (6 pairs), ± 20% (5 pairs) and ± 32% (1
pair) of the values in reference 57. There is a
strong positive correlation between the DD
cohesive surface energy and (Table 1) withγ dLW
an R2 > 0.99. Weak positive correlations also
exists between the polarizability, αp, and the
Parachor, and   versus the Parachor per unitγ dLW
molar volume with R2 >0.75 and R2 > 0.65
respectively. The dispersive energy measured
using IGC is usually higher than that obtained
with contact angle measurements because the
former probes the highest energy sites on the
powder surface. 
Table 3 Adhesive and Cohesive surface free energies, mJ/m2
EXCIPIENT












DE DE DE DE DE DE
Lactose 54.45(2.90) 19.88 23.09 28.52(4.13) 25.24(4.29) 26.22(4.28) 25.70(4.16) 79.31(2.36) 26.48(4.23)
Sucrose 67.99(2.69) 21.28 23.09 37.18(3.74) 34.36(3.80) 35.75(3.79) 35.90(3.65) 96.46(2.21) 35.49(3.78)
Mannitol 71.75(2.77) 23.85 23.09 55.19(3.25) 57.36(3.12) 59.78(3.11) 61.78(2.94) 82.74(2.53) 56.90(3.16)
Micronized
lactose
74.46(2.54) 20.77 23.09 53.37(3.09) 55.13(2.97) 57.48(2.96) 59.72(2.79) 89.83(2.27) 54.80(3.01)
Trehalose 68.17(2.67) 21.11 23.09 47.99(3.28) 48.86(3.18) 50.92(3.17) 52.50(3.00) 83.69(2.37) 48.82(3.21)
DD: Salbutamol=23.09, Budesonide=24.47, Mometasone=23.37, Formoterol=24.17, Salmeterol=22.42, Ipratropium= 22.22, Fluticasone=23.86 (calculated)
EE: The excipient-excipient cohesive energy values are same regardless of the API, therefore, this column is only presented once in the Table.
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However, both IGC and contact angle
measurements rank the dispersive component
of the free energy of pharmaceutical powders in
the same order (48). Therefore, the (relatively)
weak correlation between the contact angle
dependent attribute, the Parachor and 
should not affect the rank order of theγ dLW
calculated .γ dLW
Table 3 shows that, regardless of what excipient
they are combined with,  (DE), forΔGde
a
salbutamol and ipratropium are significantly
greater than those for the other APIs, although
they are not as pronounced in the case of
mannitol and micronized lactose. These APIs
also have the least Parachors, which is directly
related to their surface tension (and hence is
especially suited for use as a surrogate physico-
chemical attribute for surface energy related











γ is the surface tension, M the molecular
weight, dl and dv are the densities of the liquid
and vapor phase respectively and P is the
Parachor. Physico-chemical attributes such as
the Hansen solubility parameters (50),
molecular orbital indices (51) or multivariate
models using molecular descriptors (52) have
been used to predict surface properties, but
these require more data then the calculation of
the Parachor; which can be easily calculated
from the structure of the molecule using
published group or element contributors.
The Parachors of the APIs were calculated
from the group contributions presented in
reference 49 and assumed to be substantially
additive. The values were found to be accurate
within ± 5% when calculated and checked
against published values for structurally similar
steroids (53). A compound with a smaller
Parachor possesses weaker intermolecular
forces and is expected to adhere with
(relatively) greater force to excipients. When the
Parachor is divided by the molar volume, it can
be expressed in similar units as those of the
surface free energy. The Parachor per unit
volume (obtained by dividing P by Vm) is
positively correlated to the DD cohesive
surface energy, R2=0.655.
The numbers in brackets in the DE columns of
Table 3, termed the Cohesive Index, represent a
measure of how cohesive the two ingredients
(excipient and drug) are, relative to their
adhesion to each other. The CI is calculated
using Equation 4.
Eq. 4CI DD EE
DE
= ( )( )
( )
Where,
DD, EE and DE are the attributes in Table 3.
CI has a unit of .mJ
m2
This term is hence formally analogous to the
cohesive-adhesive balance (54) (CAB), with the
exception that it cannot classify the net force as
being either adhesive or cohesive (as CAB can).
Instead, the CI represents a gradation of
magnitude, the greater the CI, the greater the
cohesiveness of the components of the mixture
and vice-versa. The CI generally follows the
rank order of drug-excipient adhesive surface
energy (DE), however, it is easier to interpret
than raw DE data because, being a ratio, it is
normalized for different APIs across different
excipients. For example, a mixture of
mometasone and micronized lactose (CI=2.97)
is expected to be much more adhesive than a
mixture of budesonide and mannitol (CI=3.55).
Furthermore, all the APIs adhere more strongly
to micronized lactose (CI range=2.31-3.39)
than to non-micronized lactose (CI range=2.37-
4.28).
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Figure 1 Cohesive index as a predictor of percentage fine
particle fraction of emitted dose (FPF values from Table II
of reference 56, CI calculated from this paper)
Table 4 shows the CAB ratios obtained from
Jones et.al. (55) compared with the CI values
calculated as described above. For budesonide,
there is no correlation between the two, the
adhesive energy interaction between drug and
excipient (DE) decreasing in the order lactose
< trehalose < mannitol when measured by the
‘bulk’ IGC method (CI) while the adhesive
energy between drug and excipient decreases in
the order mannitol < trehalose < lactose when
measured by AFM (CAB). There is, similarly,
no correlation between the CI and CAB for
formoterol. The pattern for drug-adhesive
interaction is similar for salmeterol when
measured by AFM or IGC. It has been pointed
out that the separation energy measured using
AFM and the surface free energy using IGC
differ by 5 to 8 orders of magnitude. Therefore,
drug to carrier interaction forces are not
predictive of surface energy differences (30).
While an interesting academic technique,
measuring the CAB with AFM does not seem
to be representative of practical situations
encountered with the mixing of bulk drugs
and/or excipients.
Table 4 Correlation between Cohesive index and
Cohesive-adhesive balance
BUDESONIDE FORMOTEROL SALMETEROL
CI CAB CI CAB CI CAB
Lactose 4.13 0.82 4.28 1.16 4.16 2.39
Mannitol 3.25 1.12 3.11 1.18 2.94 0.65
Trehalose 3.28 1.07 3.17 1.02 3.00 1.37
Predictions made using the CAB have not
generally been replicated, and in some cases are
contradictory to, observations using IGC which
more closely mimic situations in industrial scale
mixing and size reduction operations.
Cline and Dalby (56) found a direct
proportionality between the surface energy
interaction between drug and excipient and the
FPF as a percent of emitted dose. The FPF
increased as the drug-carrier interaction became
stronger. Contrary to James et.al. (57) who
reported an order of magnitude increase in  γ +
when α-lactose monohydrate was (sub)-
micronized, these investigators did not find any
significant difference in KA values for grades of
lactose that differed in their specific surface
areas by an order of magnitude. They hence
attributed the increase of performance of the
DPI to the requirement that a minimum surface
energy interaction between drug and carrier
particles was necessary to separate the highly
cohesive, micronized drug particles during the
blending process and while the powder was
being aerosolized.
Assuming that any (adhesive) upper limit on the
reduction of agglomerates to fine particles can
be overcome by inhaler design, Table 3 shows
that the adhesive mixtures that will form the
greatest FPF are those of iprartopium with
lactose, sucrose, micronized lactose and
trehalose (CI<2.41). Conversely, adhesive
mixtures of budesonide, mometasone,
formoterol and salmeterol with lactose will
form the least FPF (CI>4.0). A plot of CI
versus FPF (FPF values obtained from
reference 34) indicates possible correlation,
shown in Figure 1, and supports the hypothesis
that a minimum adhesive surface free energy is
required between drug and carrier (within the
confines of current inhaler design) to achieve
an acceptable FPF.
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Surface energy data has been criticized as being
difficult to interpret because it is dependent on
testing conditions and does not vary
considerably among different batches. It must
be remembered that micronized or particle size
reduced mixtures of API and carrier are
thermodynamically unstable systems that are
kinetically stabilized. Knowledge of surface
energy is critical in designing optimal aerosol
yielding formulations whose surface free energy
is as less removed from the stable
thermodynamic state as possible, yet can still be
aerosolized into an acceptable FPF within
inhaler design limitations.
It is surprising that the ‘passivation hypothesis’
that explains the benefit of mixing coarse and
fine lactose powders has not been subjected to
empirical testing. This widely disseminated and
oft-referenced hypothesis posits that ‘high
energy’ sites on the coarse lactose particles are
‘occupied’ by fine lactose particles. This, in
turn, forces the API particles to occupy only
the ‘low energy’ sites on the coarse lactose
particles leading to drug-excipient adhesive
forces that can be overcome by aerosolization
and fine API particles can be generated for
deep lung delivery.
By treating non-micronized and micronized
lactose as a drug and excipient, the adhesive
energy between the two can be calculated using
Equation 1. Table 5 presents the adhesive
energy between API and lactose/micronized
lactose as well as the adhesive energy between
lactose/micronized lactose.
Table 5  Optimization of mixture blend using adhesive














Table 5 shows that the energy required to break 
interparticle bonds between lactose and
micronized lactose is 53.41 mJ/m2. The energy 
required to separate the most cohesive drug,
budesonide, is 24.47 mJ/m2. Several situations
during the mixing process can be considered:
1. The lactose and micronized lactose are
mixed together with an energy input of >
53.41 mJ/m2 during the mixing process
thereby yielding an adhesive mixture of the
two ingredients. This is then followed by
either step 2, or step 3.
2. The API is then added and the contents
mixed with an energy input of > 24.47
mJ/m2 but less than 53.41 mJ/m2. These
mixing parameters will yield a mixture that
closely resembles the one in the ‘passivation
hypothesis’, with the API particle adhering
to non-micronized lactose and the adhesion
between the non-micronized and micronized
lactose remaining unperturbed.
3. The API is then added and the contents
mixed with an energy input >53.41 mJ/m2.
In this situation, the adhesion between the
non-micronized and micronized lactose is
disrupted. API will hence predominantly
adhere to the micronized lactose component
of the excipient mixture because the
adhesive energy between the APIs presented
here and micronized lactose is greater than
that between the API and lactose. If inhaler
design is incapable of generating energy
sufficient to break these highly adhesive DE
agglomerates, a higher energy input during
mixing may decrease the FPF of the
aerosolized formulation (58).
The example outlined above emphasizes the
importance of the order of mixing (59) and the
magnitude of the energy input during mixing
processes for DPI formulations. These can
significantly impact product performance.
Additionally, IGC data for the individual
excipient/API batches as well as particle and
size distribution characterization are extremely
important in designing mixing unit operations.
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Figure 2 Molecular structure of fluticasone
This simple concept can partly explain why
conflicting data exist in the literature with
regard to FPF and a variety of surface and non-
surface (60) energy attributes for mixed DPI
powders.
Estimation of cohesive index, drug-drug
cohesive energy (DD) and drug-excipient
cohesive energy (DE) for fluticasone
The Parachor value for fluticasone, based on
the structure of the molecule (Figure 2), was











The   for fluticasone was obtained by firstγ dLW
using the line of best fit for the (P/Vm) and the 
values for the APIs, then using the line ofγ dLW
best fit for the  and DD values to obtainγ dLW
the DD for fluticasone. The  and DD forγ dLW
fluticasone were calculated to be 47.93 mJ/m2
and 23.86 mJ/m2 respectively.
For each excipient, linearised functions were
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energies on the ordinate axis for the four
monopolar APIs, budesonide, mometasone,
formoterol and salmeterol. Good correlation
was obtained for all the excipients (R2 > 0.84)
except for lactose, where the correlation
coefficient was 0.77. Substituting the value of
the calculated DD for fluticasone in the
equation for each excipient yielded a function
wherein the value of DE could be calculated.
These values are presented in Table 3. The CI
was then calculated from Equation 4.
CONCLUSIONS
Surface energy calculations from inverse gas
chromatography can yield valuable information
about how a particular API or excipient will
behave with respect to cohesive and adhesive
forces. While still simplistic in approach, the
advantage of such easily calculable data is that it
provides a starting point to not only design
experiments, but also to logically interpret
(apparently) inconsistent results from those
experiments. Using the data from four APIs
presented in this paper, the unknown cohesive
and adhesive energy for a similar (monopolar)
compound can be estimated by calculating the
surface tension (and hence surface energy)
dependent parameter, the Parachor.
The proportion of API that adheres to fine or
to coarse particles of the carrier seems to be
determined as much by the order of mixing and
the energy input during the mixing process, as it
does by the physico-chemical characteristics of
the fine/coarse carrier blend itself. Surface
energy estimations described in this report
demonstrate that the energy input during
mixing may determine the API adhesion
propensity toward different particle size
fractions of the excipient/carrier blend.
Methods to quantify the energy input during
mixing processes should be developed and
reported so that FPF data may be contextually
interpreted (61). Additionally, the energy input
must include the dimensionality of Time
because the adhesion energy of particles to a
substrate surface increases with the force with
which the particles are pressed against the
surface (press-on force) (62). Time dependent,
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repeated application of the same force has the
same effect as increasing the press-on force.
Salbutamol has been disproportionately used as
a representative API in published papers. Since
salbutamol exhibits the greatest drug-excipient
adhesive energies (after ipratropium) with
mixtures of micronized and non-micronized
lactose monohydrate (the most commonly used
excipient blend in DPI), the adhesive forces in
a mixture of salbutamol and lactose will be
greater than those with other APIs in
combination with lactose. Therefore,
phenomena of separation or segregation of
ingredients over shelf life and dose non-
uniformity will be lesser with salbutamol-
lactose mixtures. In addition, depending on the
magnitude of the CI and the design of the
inhaler, FCAs will be lesser able to influence
(improve) the FPF of the dispensed aerosol. If
conclusions from such experiments are
generalized, the attributes of  separation of the
drug-carrier mixture over shelf life, dose non-
uniformity as well as the importance of FCAs
to increase performance post-aerosolization will
be perceived to be less important in designing
DPI formulations. To alleviate this skewed
perception, it is recommended that, whenever
possible, experiments be performed using APIs
that represent both the upper and lower limit of
API-excipient interactions in terms of surface
energetics, i.e. both monopolar and dipolar
APIs be included.
The large number of variables that affect
particle-particle interactions, and their
interdependence, stymies cause-and-effect
conclusions and encourages the execution of
more empirical studies, in the hope of
eventually accumulating unequivocal evidence
of causality (and hence prediction). Regardless
of suggestions to the contrary (63), it is useful
to attempt generalizations based on what
(inconclusive) data exists, so that a particular
direction and strategy for future research may
either become evident or be discarded. The
quantification of surface energetics using an
easily calculable molecular structural constant as
a tool for prediction of DPI behavior
represents such an attempt. It is hoped that this
model may be further developed such that the
ultimate objective of prediction may be
achieved.
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